Tagged with innovation

Belgium In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European and global ecosystem. Here we highlight some of the key themes of the discussions: innovation, generics and biosimilars, and teamwork.…

Belgium Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her…

Opinion Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) highlights the leaps and bounds with which the Chinese pharmaceutical industry has developed in recent years, the country’s increasingly important role in the global innovation landscape, and why cross-border collaboration is more crucial than ever in the…

UAE PharmaBoardroom’s latest country report gives an up-to-date and comprehensive overview of one of the most strategic and innovation-friendly nations on earth: The UAE.   The UAE’s pharma market was predicted to grow to USD four billion in 2020, representing a CAGR of 8.5 percent from 2019. The country sits at…

Belgium Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy.  …

Belgium Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate on the vast commitment Roche has to the Belgian market and the company’s mission not only to drive innovation but…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Belgium Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an innovative specialty pharma player balancing a core business with an increasing focus on specialty areas. He also offers insights on…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

Mexico Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing innovative treatments to what is a still-developing market.   A new set of rules is emerging in Mexican healthcare Fernando,…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Europe EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation.   If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate…